Chemotherapy and radiation therapy have minimal benefit in advanced renal cell carcinoma; however, survival is extended by treatment with tyrosine kinase inhibitors targeting VEGF, MTOR inhibitors, and immunotherapy. This evidence concerns the gene VEGFA and hereditary clear cell renal cell carcinoma.